Susquehanna International Group, LLP Dynavax Technologies Corp Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

A detailed history of Susquehanna International Group, LLP transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Susquehanna International Group, LLP holds 71,415 shares of DVAX stock, worth $806,989. This represents 0.0% of its overall portfolio holdings.

Number of Shares

71,415

Previous 141,678 49.59%

Holding current value

$806,989

Previous $1.76 Million 54.44%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$10.73 - $12.58 $753,921 - $883,908	-70,263 Reduced 49.59%	71,415 $801,000
Q1 2024 May 07, 2024	BUY	$11.7 - $14.98 $1.16 Million - $1.49 Million	99,488 Added 235.81%	141,678 $1.76 Million
Q4 2023 Feb 14, 2024	SELL	$13.09 - $14.98 $204,701 - $234,257	-15,638 Reduced 27.04%	42,190 $589,000
Q3 2023 Nov 14, 2023	BUY	$12.64 - $14.99 $127,701 - $151,443	10,103 Added 21.17%	57,828 $854,000
Q2 2023 Aug 11, 2023	SELL	$9.85 - $13.17 $2.55 Million - $3.41 Million	-258,661 Reduced 84.42%	47,725 $616,000
Q1 2023 May 16, 2023	BUY	$9.44 - $11.88 $2.05 Million - $2.58 Million	216,862 Added 242.24%	306,386 $3.01 Million
Q4 2022 Feb 14, 2023	SELL	$10.27 - $13.29 $3.31 Million - $4.28 Million	-321,958 Reduced 78.24%	89,524 $952,000
Q3 2022 Nov 14, 2022	BUY	$9.93 - $17.44 $3.25 Million - $5.71 Million	327,463 Added 389.75%	411,482 $4.3 Million
Q2 2022 Aug 15, 2022	SELL	$7.45 - $12.83 $4.28 Million - $7.36 Million	-573,990 Reduced 87.23%	84,019 $1.06 Million
Q1 2022 May 16, 2022	SELL	$9.75 - $14.44 $744,929 - $1.1 Million	-76,403 Reduced 10.4%	658,009 $7.13 Million
Q4 2021 Feb 14, 2022	SELL	$13.17 - $20.94 $2.67 Million - $4.24 Million	-202,626 Reduced 21.62%	734,412 $10.3 Million
Q3 2021 Nov 15, 2021	BUY	$9.16 - $19.83 $2.47 Million - $5.34 Million	269,228 Added 40.32%	937,038 $18 Million
Q2 2021 Aug 11, 2021	BUY	$7.25 - $10.99 $58,420 - $88,557	8,058 Added 1.22%	667,810 $6.58 Million
Q1 2021 May 17, 2021	SELL	$4.57 - $11.18 $55,105 - $134,808	-12,058 Reduced 1.79%	659,752 $6.49 Million
Q4 2020 Feb 16, 2021	SELL	$3.73 - $5.6 $729,233 - $1.09 Million	-195,505 Reduced 22.54%	671,810 $2.99 Million
Q3 2020 Nov 16, 2020	BUY	$4.32 - $11.7 $1.64 Million - $4.43 Million	378,877 Added 77.57%	867,315 $3.75 Million
Q2 2020 Aug 14, 2020	BUY	$2.94 - $9.1 $930,495 - $2.88 Million	316,495 Added 184.07%	488,438 $4.33 Million
Q1 2020 May 15, 2020	BUY	$2.27 - $6.2 $139,296 - $380,456	61,364 Added 55.49%	171,943 $607,000
Q4 2019 Feb 14, 2020	SELL	$3.46 - $6.93 $751,809 - $1.51 Million	-217,286 Reduced 66.27%	110,579 $633,000
Q3 2019 Nov 14, 2019	BUY	$2.69 - $4.85 $587,353 - $1.06 Million	218,347 Added 199.37%	327,865 $1.17 Million
Q2 2019 Aug 16, 2019	BUY	$3.65 - $7.89 $26,750 - $57,825	7,329 Added 7.17%	109,518 $437,000
Q2 2019 Aug 14, 2019	BUY	$3.65 - $7.89 $201,892 - $436,419	55,313 Added 118.0%	102,189 $408,000
Q1 2019 May 15, 2019	SELL	$7.08 - $12.09 $809,435 - $1.38 Million	-114,327 Reduced 70.92%	46,876 $343,000
Q4 2018 Feb 14, 2019	SELL	$8.14 - $13.28 $136,133 - $222,094	-16,724 Reduced 9.4%	161,203 $1.48 Million
Q3 2018 Nov 14, 2018	SELL	$11.85 - $16.0 $364,897 - $492,688	-30,793 Reduced 14.75%	177,927 $2.21 Million
Q2 2018 Aug 14, 2018	BUY	$15.15 - $20.75 $269,851 - $369,599	17,812 Added 9.33%	208,720 $3.18 Million
Q1 2018 May 15, 2018	BUY	$14.65 - $19.9 $55,845 - $75,858	3,812 Added 2.04%	190,908 $3.79 Million
Q4 2017 Feb 14, 2018	SELL	$17.3 - $24.08 $2,941 - $4,093	-170 Reduced 0.09%	187,096 $3.5 Million
Q3 2017 Nov 14, 2017	BUY	$15.2 - $21.5 $2.85 Million - $4.03 Million	187,266	187,266 $4.03 Million

Others Institutions Holding DVAX

# of Institutions

259

Shares Held

132M

Call Options Held

371K

Put Options Held

99.2K

View Full List

About DYNAVAX TECHNOLOGIES CORP

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.43B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

More about DVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Dynavax Technologies Corp Transaction History